Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Cannabidiol improves symptoms of canine arthritis, study finds
Arthritis affects one in five dogs.

Scientists measure the effect of CBD in dogs diagnosed with the condition. 

Scientists in the United States have discovered that cannabidiol (CBD) can significantly improve the lives of dogs diagnosed with arthritis.

The researchers, from the Baylor College of Medicine in Texas, say their results could pave the way to studying the effects of CBD in humans.

In the study, the scientists first measured the effect of CBD on immune responses associated with arthritis, both in human and murine cells grown in the lab and mouse models. They found that that CBD treatment resulted in reduced production of both inflammatory molecules and immune cells linked to arthritis.

Next, the researchers found that in dogs diagnosed with the condition, CBD treatment significantly improved quality of life as documented by both owner and veterinary assessments. Scientists say their work, published in the journal PAIN, supports future scientific evaluation of CBD for human arthritis.

“We found encouraging results,” said Dr Matthew Halpert, research faculty in the department of pathology and immunology at Baylor. “Nine of the 10 dogs on CBD showed benefits, which remained for two weeks after the treatment stopped. We did not detect alterations in the blood markers we measured, suggesting that, under the conditions of our study, the treatment seems to be safe.”

Arthritis affects one in five dogs, and its prevalence increases as a dog ages, according to Canine Arthritis Management.

Twenty dogs from the Sunset Animal Hospital in Houston were employed for the study. The dogs' owners were given medicine bottles at random, containing either CBD, liposomal CBD, or a placebo. Neither the owner nor the vet knew which treatment each dog was receiving.

The dogs received the treatment each day for four weeks. The vet and the dogs' owners noted the condition of the dogs and whether they noticed any changes in their animal's level of pain, such as changes related to running or gait. The dogs' blood cell count, liver and kidney function were also evaluated before and after treatment.

“We studied dogs because experimental evidence shows that spontaneous models of arthritis, particularly in domesticated canine models, are more appropriate for assessing human arthritis pain treatments than other animal models," said Halpert. "The biological characteristics of arthritis in dogs closely resemble those of the human condition."

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.